Alvotech and teva secure u.s. license date for avt04, a proposed biosimilar to stelara®

Reykjavik, iceland & tel aviv, israel & parsippany, n.j.--(business wire)--alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and teva pharmaceuticals, inc., a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced they have reached a settlement and license agreement with johnson & johnson (nyse:jnj) concerning avt04, alvotech's proposed biosimilar to stelara®.
ALVO Ratings Summary
ALVO Quant Ranking